Loading clinical trials...
Loading clinical trials...
Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy
Conditions
Interventions
Olmesartan medoxomil
Losartan
Locations
27
Czechia
Frýdlant, Czechia
Liberec, Czechia
Prague, Czechia
Tartu, Estonia
Augsburg, Germany
Greifenstein-Beilstein, Germany
Start Date
May 1, 2003
Completion Date
September 1, 2004
Last Updated
October 9, 2006
NCT07051005
NCT06887049
NCT04943861
NCT07433062
NCT07351786
NCT05099770
Lead Sponsor
Sankyo Pharma Gmbh
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions